Nymox Pharmaceutical Reports Completion Of NX-1207 Dosing In Current Multi-Center BPH Drug Trial

HASBROUCK HTS., N.J.--(BUSINESS WIRE)--June 9, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) announced today that patient dosing in the Company's multi-center Phase 2 clinical trial of NX-1207 is completed this week. NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), a common affliction of men over the age of 50.

Back to news